åæ¥æ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Sarepta Therapeutics, Inc. ã¯ãåžå°çŸæ£ã®æ²»çãç®çãšãã RNA æšçæ²»çè¬ãéºäŒåæ²»çãããã³ãã®ä»ã®éºäŒåæ²»çæ§åŒã®çºèŠãšéçºã«æ³šåããŠããŸããå瀟ã¯ããšã¯ãœã³ 51 ã¹ãããã³ã°ã®åœ±é¿ãåãã DMD éºäŒåã®å€ç°ã確èªãããæ£è
ã®ãã¥ã·ã§ã³ãåçãžã¹ãããã£ãŒ (DMD) ã®æ²»çè¬ãšã㊠EXONDYS 51 泚å°å€ãããã³ãšã¯ãœã³ 53 ã¹ãããã³ã°ã®åœ±é¿ãåãã DMD éºäŒåã®å€ç°ã確èªãããæ£è
ã® DMD ã®æ²»çè¬ãšã㊠VYONDYS 53 ãæäŸããŠããŸãããŸãããã¹ãããžã¢ãããŒã ã¢ã«ããªã ãªãªãŽã㌠(PMO) ååŠãšãšã¯ãœã³ ã¹ãããã³ã°æè¡ã䜿çšããŠãžã¹ãããã£ã³éºäŒåã®ãšã¯ãœã³ 45 ãã¹ããããã補ååè£ã§ãã AMONDYS 45ããžã¹ãããã£ã³ pre-mRNA ã®ãšã¯ãœã³ 51 ã«çµåããããããçµå PMO ã§ãã SRP-5051 ãéçºããŠããŸãã SRP-9001ïŒDMDãã€ã¯ããžã¹ãããã£ã³éºäŒåæ²»çããã°ã©ã ïŒãããã³SRP-9003ïŒè¢åž¯åçãžã¹ãããã£ãŒéºäŒåæ²»çããã°ã©ã ïŒãªã©ã®éºäŒåæ²»çããã°ã©ã ãéçºããŠããŸããå瀟ã¯ãF. Hoffman-La Roche LtdãNationwide Children's HospitalãLysogeneãDuke UniversityãGenethonãStrideBioãšååå¥çŽãçµãã§ããŸãããŸããCodiak BioSciences, Inc.ãšã®ç ç©¶ããã³ãªãã·ã§ã³å¥çŽãç· çµããŠãããç¥çµççŸæ£ã®éºäŒåæ²»çãéºäŒåç·šéãRNAæè¡ãå®çŸãã人工ãšã¯ãœãœãŒã æ²»çè¬ã®èšèšãšéçºãè¡ã£ãŠããŸãããŸããGenevant Sciencesãšè質ããç²åããŒã¹ã®éºäŒåç·šéæ²»çè¬ã®ç ç©¶ååãè¡ã£ãŠããŸããSarepta Therapeutics, Inc.ã¯1980幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã±ã³ããªããžã«æ¬ç€Ÿã眮ããŠããŸãã